HSBC/PUT/MODERNA/130/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 20:35:43 28/06/2024 BST | ||
| 2.26 EUR | +5.61% |
|
| Current month | +54.79% | ||
| 1 month | +82.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 2.26 | +5.61% |
| 27/06/24 | 2.14 | +4.39% |
| 26/06/24 | 2.05 | +31.41% |
| 25/06/24 | 1.56 | +0.65% |
| 24/06/24 | 1.55 | -6.63% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 08:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG8KD3 |
| ISIN | DE000HG8KD36 |
| Date issued | 28/02/2023 |
| Strike | 130 $ |
| Maturity | 15/01/2025 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 2.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.13 € |
|---|---|
| Lowest since issue | 1 € |
| Spread | 0.02 € |
| Spread % | 0.88% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
